Pharmaceutical Technology

JULY 14, 2025

Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock. Give your business an edge with our leading industry insights.

Labelling

Pharmaceutical Technology

JULY 22, 2025

It is important for the patients we serve that Sarepta maintains a productive and positive working relationship with FDA, and it became obvious that maintaining that productive working relationship required this temporary suspension while we address any questions that FDA may have and complete the Elevidys label supplement process.”

Insurance Coverage and Processing

Pharmaceutical Technology

JULY 29, 2025

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Despite being a different drug, it is built on the same viral vector as Elevidys, a recombinant adeno-associated viral vector (AAV) called AAVrh74.

Insurance Coverage and Processing

Pharmaceutical Technology

JULY 14, 2025

The company is confident that these concerns, which pertain to facilities and processes rather than product quality, can be promptly addressed. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications.

Insurance Coverage and Processing

Pharmaceutical Technology

JULY 25, 2025

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. GlobalData is the parent company of Clinical Trials Arena. Topic sponsors are not involved in the creation of editorial content.

Insurance Coverage and Processing

Pharmaceutical Technology

JULY 30, 2025

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. His exit raises critical questions: which evidence standards will prevail: traditional or accelerated?” Sign up for our daily news round-up!

Insurance Coverage and Processing

pharmaphorum

JULY 7, 2025

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insurance Coverage and Processing

Beckers Hospital Review

AUGUST 1, 2025

Mr. Angelone, co-founder and chief commercial officer of MacroHealth, has over 25 years of experience in the health insurance and technology industries. Mr. Angelone has also ensured compliance with key regulations like the No Surprises Act and Transparency in Coverage rules, promoting greater transparency in healthcare pricing.

Insurance Coverage and Processing

Pharmaceutical Technology

JULY 17, 2025

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!

Insurance Coverage and Processing

Pharmaceutical Technology

AUGUST 7, 2025

mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Shares of key sector players such as Moderna and BioNTech remain stable, with values reducing by 2.8% and increasing by 0.21% respectively, suggesting that investors still have hope for the modality.

Insurance Coverage and Processing

Putting Patients First Blog

JULY 2, 2024

We believe that patient-centric engagement is essential to ensure that the negotiation process leads to outcomes that genuinely benefit patients. Patient Engagement The NHC recognizes and commends CMS’ willingness to improve the listening sessions and the data submission processes. Improving the Data Collection (ICR) Process.

Drug Pricing

Putting Patients First Blog

JULY 15, 2024

The DDIWG should actively seek input from individuals with disabilities who also belong to other marginalized groups, such as people of color, LGBTQ+ individuals, and low-income communities. This process respects their autonomy by involving them in decision-making to the extent that they are able.

Health and Personal Care Stores